PRLD
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Prelude announces a clinical trial collaboration and supply agreement with Lilly to evaluate the selective KAT6A degrader PRT13722 combined with Verzenio and Inluriyo in patients with HR-positive/HER2-negative breast cancerOct 13, 2026
- FDA cleared Prelude Therapeutics' IND application for PRT13722, a first-in-class oral selective KAT6A degraderSep 10, 2026